Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line

Gastrointestinal Cancer

Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy

healthbook Times Oncology Hematology

Palmarocchi MC, Merlo E, Cefali M, De Dosso S

doi: 10.36000/hbT.OH.2021.07.029

A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review

Oncotarget.

Rosati LM, Kummerlowe MN, Poling J, Hacker-Prietz A, Narang AK, Shin EJ, Le DT, Fishman EK, Hruban RH, Yang SC, Weiss MJ, Herman JM

doi: 10.18632/

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Gastrointestinal Cancer

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion

Ann Oncol.

O'Reilly EM, Hechtman JF

doi: 10.1093/annonc/mdz385.

Radio-Oncology

Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports

J Breast Cancer.

Byun KD, Ahn SG, Baik HJ, Lee A, Bae KB, An MS, Kim KH, Shin JH, Park HK, Cho H, Jeong J, Kim TH.

doi: 10.4048/jbc.2016.19.2.214.

Breast CancerGastrointestinal Cancer

Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia

doi: 10.21873/anticanres.13022.

Gastrointestinal CancerSkin Cancer

Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy

Cancer Biol Ther.

Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS

doi: 10.1080/

Lung, Respiratory and Thoracic Cancer

First-line treatment of ALK-positive NSCLC

healthbook TIMES Oncology Hematology

Bouchaab H

doi: 10.36000/hbT.OH.2019.02.008

Breast Cancer

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Lancet Oncol.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators

doi: 10.1016/

Related content